Enhabit, Inc. (EHAB) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
EHAB's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
EHAB Revenue Analysis (2020–2024)
As of March 1, 2026, Enhabit, Inc. (EHAB) generated trailing twelve-month (TTM) revenue of $1.05 billion, reflecting modest growth of +3.9% year-over-year. The most recent quarter (Q3 2025) recorded $263.6 million in revenue, down 0.9% sequentially.
Looking at the longer-term picture, EHAB's historical revenue data shows a 3-year CAGR of -2.2%. The company achieved its highest annual revenue of $1.11 billion in 2021.
Revenue diversification analysis shows EHAB's business is primarily driven by Home Health Segment (100%). With over half of revenue concentrated in Home Health Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CHE (+4.1% YoY), OPCH (+13.0% YoY), and ADUS (+23.2% YoY), EHAB has underperformed the peer group in terms of revenue growth. Compare EHAB vs CHE →
Peer Comparison
Compare EHAB's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EHABCurrent | $1.0B | +3.9% | - | -11.1% | |
| CHE | $2.5B | +4.1% | +4.0% | 13.4% | |
| OPCH | $5.6B | +13.0% | +13.3% | 6.0% | |
| ADUS | $1.4B | +23.2% | +13.2% | 9.7% | |
| AVAH | $2.0B | +11.5% | +7.9% | 6.9% | |
| DCGO | $617M | -47.0% | +66.4% | 4.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.03B | -1.1% | $504.0M | 48.7% | $-115,100,000 | -11.1% |
| 2023 | $1.05B | -2.3% | $510.7M | 48.8% | $-47,600,000 | -4.5% |
| 2022 | $1.07B | -3.2% | $545.5M | 50.9% | $-11,400,000 | -1.1% |
| 2021 | $1.11B | +2.6% | $592.7M | 53.6% | $142.9M | 12.9% |
| 2020 | $1.08B | - | $540.7M | 50.1% | $102.7M | 9.5% |
See EHAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EHAB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare EHAB vs AGIO
See how EHAB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is EHAB's revenue growth accelerating or slowing?
EHAB revenue growth slowed to +3.9%, below the 5-year CAGR of N/A. TTM revenue is $1.0B. The deceleration marks a shift from historical growth rates.
What is EHAB's long-term revenue growth rate?
Enhabit, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of +3.9% is near this long-term average.
How is EHAB's revenue distributed by segment?
EHAB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.